Articles from ADC Therapeutics SA

LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 113,700 of the Company’s common shares to six new employees on October 1, 2024 (each, a “Grant”).

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company’s common shares to four new employees on September 3, 2024 (each, a “Grant”).

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September:

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024

LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 38,600 of the Company’s common shares to three new employees on August 1, 2024 (each, a “Grant”).

LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarter 2024 and provide operational updates.

LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 172,400 of the Company’s common shares to six new employees on July 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET.

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET.

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million. The offering is expected to close on May 8, 2024, subject to customary closing conditions.

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA®

LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company’s common shares to four new employees on May 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress against key catalysts from the pipeline.

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company’s novel exatecan-based antibody drug conjugate platform. A live question and answer session will follow the presentations.

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates.

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b

LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 at 9:50 a.m. ET.

LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 over a consecutive 30 trading-day period. As closing price of the common shares on December 29, 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29, 2023 were both above $1.00, the deficiency was cured.

ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023

Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.

3Q 2023 ZYNLONTA®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT.

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for the third quarter 2023 and provide business updates.

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals

2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.

BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSEADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA® (loncastuximab tesirine-lpyl), which is seeking an indication for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy in China. The BLA has been granted priority review by the NMPA.

LAUSANNE, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it plans to discontinue the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Given the challenges of defining the addressable segment of the difficult-to-treat unfit or frail DLBCL patient population, including many patients with significant active underlying co-morbidities, the benefit-risk profile does not support continuation of the LOTIS-9 trial.

LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (ClinicalTrials.gov Identifier: NCT05144009) evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML

LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8th at 8:30 a.m. EDT.

ADC Therapeutics SA (NYSEADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.

ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16th at 10:00 a.m. EDT.

ADC Therapeutics SA (NYSEADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy.

ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates.

ADC Therapeutics SA (NYSEADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”).

ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET.

ADC Therapeutics SA (NYSEADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.

ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.

ADC Therapeutics SA (“ADCT” or the “Company”) (NYSEADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates, today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the “Selling Shareholder”), an affiliate of Auven Therapeutics Holdings L.P., at a price of $5.00 per share (before underwriting discounts and commissions). ADCT is not selling any common shares and will not receive any proceeds from the sale of the common shares in the offering. The offering is expected to close on February 6, 2023, subject to customary closing conditions.

ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.

ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT.

ADC Therapeutics SA (NYSEADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community.

ADC Therapeutics SA (NYSEADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Sobi expects to commence launching ZYNLONTA upon completion of the marketing authorization transfer.

ADC Therapeutics SA (NYSEADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities.

ADC Therapeutics SA (NYSEADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates.

ADC Therapeutics SA (NYSEADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

ADC Therapeutics SA (NYSEADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA® (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, Louisiana from December 10-13, 2022.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSEADCT) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA® (loncastuximab tesirine-lpyl), ADC Therapeutics’ CD19-directed antibody drug conjugate (ADC), for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).

ADC Therapeutics SA (NYSEADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective November 1, 2022. Both Ms. Harrington-Smith and Mr. Graham will serve on the Company’s leadership team.

ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.

ADC Therapeutics SA (NYSEADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.

ADC Therapeutics SA (NYSEADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion from the CHMP is now referred to the European Commission for an approval decision.

ADC Therapeutics SA (NYSEADCT) today announced that it has completed a series of strategic transactions in which it:

ADC Therapeutics SA (NYSEADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates.

ADC Therapeutics SA (NYSEADCT) today announced the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors.

ADC Therapeutics SA (NYSEADCT) today announced the first patient has been dosed in LOTIS-9, a Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in unfit and frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals (“Overland”) and ADC Therapeutics SA (NYSEADCT), today announced the first patient has been dosed in China with ZYNLONTA® in combination with rituximab compared to standard immunochemotherapy in the LOTIS-5 confirmatory Phase 3 global clinical trial in second-line or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL).

ADC Therapeutics SA (NYSEADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan drug designation was granted for ZYNLONTA for the treatment of diffuse large B-cell lymphoma (DLBCL) in Europe. ADC Therapeutics and Sobi intend to make ZYNLONTA available following a regulatory decision that is expected by the first quarter of 2023.

ADC Therapeutics SA (NYSEADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company’s Chief Executive Officer in May 2022, will join the Board.

ADC Therapeutics SA (NYSEADCT) today announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

ADC Therapeutics SA (NYSEADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective July 1st. In this role, Mr. Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the Company’s executive leadership team.

ADC Therapeutics SA (NYSEADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET.